---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-087893"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:21:59.337349+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q2 net revenue up 20% to $18.3M; loss narrows to $7.5M

## Summary
- Net revenue $18.3M (+20% YoY), driven by new product launches despite Targadox generic competition.
- Net loss $7.5M ($0.43/sh) vs. $11.9M ($1.30/sh) in Q2 2021; Adjusted EBITDA loss $2.6M.
- DFD-29 Phase 3 rosacea trials 45% enrolled; top-line data expected H1 2023, NDA in H2 2023.
- Settlement with Padagis solidifies exclusivity for QBREXZA, AMZEEQ, ZILXI; supply chain delays resolved.
- Tenth dermatology product launch planned in H2 2022; salesforce expanded from 42 to 84 reps.

## SEC filing metadata
- accession: 0001104659-22-087893
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465922087893/0001104659-22-087893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465922087893/tm2222960d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-087893
- JSON: https://secwatch.observer/filing/0001104659-22-087893.json
- Plain text: https://secwatch.observer/filing/0001104659-22-087893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.